$VTRS

Campbell Paul sold $810K of VTRS

Campbell Paul (See Remarks) sold 50,076 shares of Viatris Inc (VTRS) at $16.17 ($0.81M total) on 2026-06-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Campbell Paul
Published Jun 26, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 26, 2026, 9:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$VTRS
Neutral
medium confidence
Mentioned
$VTRS
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VTRSNeutralLow
01

Why it matters

The newest fact is the disclosed open-market sale size, price, and post-transaction holdings; it can marginally influence sentiment but does not change fundamentals by itself.

02

Market read

A scheduled insider sale under 10b5-1 is typically low-signal; any trading impact is likely limited unless part of a broader pattern.

03

What to watch

Traders may over-weight single insider sales; without context on prior insider activity, net selling trend, or concurrent fundamentals, the signal is weak.

Relevance 4/10Novelty 5/10Timing: after-hours/filing time (Form 4 filed 2026-06-26)

Background

The article is an SEC Form 4 insider transaction disclosure for Viatris (VTRS).

Company-level read

Ticker impact

$VTRSNeutralMedium confidence
Context

Viatris insider Campbell Paul sold 50,076 shares at $16.1711 via an open-market transaction under a 10b5-1 plan, per Form 4 filed June 26.

Expected impact

Likely limited near-term price impact; any effect should be small and fade unless followed by additional insider selling or fundamental news.

Evidence & confidence

The filing is a primary-source Form 4, but it specifies a pre-arranged 10b5-1 plan and the article provides no accompanying fundamental catalyst.

Market effects

No sector read-through; this is company-specific insider transaction data only.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity rather than a change in outlook.

Key entities

  • Viatris Inc

    Subject of the Form 4 insider transaction disclosure.

  • Campbell Paul

    Officer who executed the open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$VTRSMedAI 8/10

Viatris (VTRS) Gains Japan WAKIX Approval As Fair Value Still Sits Higher

Viatris (VTRS) received Japanese approval for WAKIX, expanding its market. The stock is up 36% YTD and 77% over 1 year, closing at $16.95. Analysts estimate a fair value of $18.50, suggesting an 8% undervaluation. The company expects long-term growth from aging populations and chronic disease prevalence, but faces risks from generic price pressure and integration costs.

$VTRSMed

Piper Sandler raises Viatris stock price target on patch growth

Piper Sandler raised its price target for Viatris (VTRS) to $13.00, citing growth in its estradiol patch business and upcoming Phase III readouts. The stock is up 80% over the past year, trading at $16.65. Viatris reported better-than-expected Q2 2026 earnings and revenue, raising its full-year guidance. Piper Sandler maintains a Neutral rating, noting risks tied to biosimilars and clinical trial outcomes.

$VTRSHighAI 9/10

Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome

Viatris Inc. (VTRS) received approval in Japan for WAKIX® (pitolisant) to treat narcolepsy and excessive daytime sleepiness in obstructive sleep apnea syndrome. This is the first histamine H3 receptor antagonist/inverse agonist approved for these conditions in Japan, addressing a high unmet medical need. The approval was supported by clinical trial data.

$VTRSLow

Viatris names Kim Sun-A head of Japan-Korea cluster

Viatris Korea appointed Kim Sun-A to lead its new Japan-Korea cluster, overseeing strategy and collaboration between the regions. She retains her role as president of Viatris Japan. The move aims to boost cooperation between the countries' operations. Bill Schuster remains president of Viatris Korea, managing its local operations.

$VTRSLowAI 8/10

Nightly Eye Drop Tested for Night Driving Glare Improved Dim-Light Vision in One in Five Adults in Trial

A phase 3 trial of 0.75% phentolamine eye drops by Opus Genetics and Viatris showed 21% of adults with night vision issues improved on a dim-light eye chart after 15 days, compared to 3% on placebo. The drop, not yet FDA-approved for night vision, aims to reduce glare and halos. Results were published in the American Journal of Ophthalmology. A confirmatory trial is expected in 2026.

$VTRSMedAI 8/10

Viatris (VTRS) Q2 2026 Earnings Call Transcript

Viatris (VTRS) reported Q2 2026 revenue of $3.8B, up 3.5% operationally, with adjusted EBITDA of $1.2B and adjusted EPS of $0.69. Management raised 2026 guidance for revenue ($14.55B-$14.95B), adjusted EBITDA ($4.3B-$4.5B) and adjusted EPS ($2.45-$2.59). It also cited Nashik supply disruptions and FDA approval for its Gwyn Lo patch.